Phenome-wide association study data suggested that modulating DGKD, CASR, CYP24A1, or SLC34A1 may result in target-mediated adverse effects including alterations in serum bilirubin, inflammatory bowel disease, migraine, atopic dermatitis, and eczematous phenotypes (Supplemental Data 4) (9). This evidence concerns the gene CYP24A1 and atopic eczema.